Search

Acupath LABORATORIES INC., Biomarkers, Bladder Cancer, Business, Cancer, Cancer Biomarkers, Carcinoma Biomarkers, Cytology, Diagnostics and Screening, Health and Medicine, Oncology, Risk and Prevention Keywords: Acupath LABORATORIES INC.; Biomarkers; Bladder Cancer; Business; Cancer; Cancer Biomarkers; Carcinoma Biomarkers; Cytology; Diagnostics and Screening; Health and Medicine; Oncology; Risk and Prevention EN Acupath LABORATORIES INC. Biomarkers Bladder Cancer Business Cancer Cancer Biomarkers Carcinoma Biomarkers Cytology Diagnostics and Screening Health and Medicine Oncology Risk and Prevention 69 69 1 09/19/23 20230919 NES 230919 2023 SEP 19 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Acupath Labs released a white paper highlighting the impressive results of a large-scale internal study analyzing the clinical utility of its Acu-UR017 bladder cancer biomarker. [Extracted from the article]

A new editorial paper published in Oncotarget discusses acute myeloid leukemia (AML), a type of aggressive cancer. The paper highlights recent advancements in understanding AML biology and the potential for developing novel drug therapies. The researchers suggest exploring reductive carboxylation as a possible drug target to weaken tumor cell survival mechanisms and improve patient outcomes. The paper provides further information on this topic and can be accessed through the provided DOI link. [Extracted from the article]

A recent editorial paper published in Oncotarget discusses the therapeutic potential and challenges of cytostatic persister cancer cells. These cells are able to remain viable despite treatment and can contribute to residual diseases and the emergence of resistant clones and relapses. Unlike resistant cells, persister cancer cells enter a non-proliferating state that is reversible upon treatment discontinuation. The paper highlights the need to understand the properties of cytostatic persisters and explores strategies for targeting them to reduce cancer recurrence. The researchers suggest that administering multiple targeted regimens may be necessary to effectively deplete the persister reservoirs in patients undergoing cancer treatments. [Extracted from the article]

A recent editorial paper published in Oncotarget discusses the molecular functions of regulatory genetic variants associated with cancer. The paper highlights the challenges in understanding the effects of genetic variants, such as their small effect size and their location in non-protein-coding regions of the genome. The researchers propose integrating genomic, epigenomic, transcriptomic, and machine learning methods to identify functional genetic variants and characterize their mode of action in regulating target genes. This approach has implications for cancer research and precision medicine. [Extracted from the article]

A research paper published in Oncotarget's Volume 15 discusses the differential expression of the Mad2 gene in human esophageal cancer. The study focuses on the relationship between the consumption of raw areca nut and the development of esophageal squamous cell carcinoma (ESCC). The researchers found that Mad2 expression levels were both overexpressed and underexpressed in the samples, leading to premature anaphase and chromosome missegregation. The study suggests that Mad2 expression levels, along with chromosomal abnormalities, could serve as a clinical biomarker for esophageal cancer. Further research is needed to understand the role of the pRb-E2F1 circuit in Mad2 down-regulation. [Extracted from the article]

A recent study conducted in Finland aimed to determine the frequency of NTRK gene fusion in patients with papillary thyroid cancer (PTC). The researchers identified patients with PTC from Finland's Auria Biobank and analyzed their genetic alterations, clinical characteristics, disease progression, and treatment pathways. The study found that NTRK gene fusion was infrequent in PTC patients, with only 1.5% of patients having the fusion. The study also demonstrated the feasibility of linking biobank samples to electronic health records to describe patient characteristics and outcomes. [Extracted from the article]

Keywords for this news article include: Cancer, Business, Oncology, Natera Inc., Health and Medicine. Business, Cancer, Health and Medicine, Natera Inc., Oncology Keywords: Business; Cancer; Health and Medicine; Natera Inc.; Oncology EN Business Cancer Health and Medicine Natera Inc. Oncology 425 425 1 05/22/23 20230523 NES 230523 2023 MAY 23 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, reported financial results for the first quarter ended March 31, 2023. [Extracted from the article]

Keywords: Business; Cancer; Health and Medicine; Healthcare Biotechnology Companies; Investment and Finance; Oncology; Veracyte Inc EN Business Cancer Health and Medicine Healthcare Biotechnology Companies Investment and Finance Oncology Veracyte Inc 1182 1182 1 05/15/23 20230516 NES 230516 2023 MAY 16 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Veracyte, Inc. (Nasdaq: VCYT) announced financial results for the first quarter ended March 31, 2023. Business, Cancer, Health and Medicine, Healthcare Biotechnology Companies, Investment and Finance, Oncology, Veracyte Inc "In addition, we further enhanced our Afirma test, as well as augmented the clinical evidence in support of adoption and reimbursement of our products, ultimately helping to advance our vision of transforming cancer care for patients all over the world.". [Extracted from the article]

A new study from Amrita Vishwa Vidyapeetham in Kerala, India explores the challenges faced during implant-assisted prosthetic rehabilitation in fibula reconstructed jaws for head and neck cancer patients. The study aims to gather evidence on the difficulties and corrective measures in prosthetic rehabilitation for this population. The researchers will conduct a scoping review using the Joanna Briggs Institute protocol and will search databases such as PubMed, Scopus, and Google Scholar for relevant articles published in the past 20 years. The findings will contribute to improving prosthetic treatment care for individuals with fibula-reconstructed head and neck cancer. [Extracted from the article]

A recent report from Pfizer Research & Development discusses the analysis of longitudinal data in the context of bladder cancer. The researchers developed a Bayesian Bernoulli-Exponential model to account for varying visit times and unbalanced data. Through statistical simulations, they assessed the model's performance and found that it performed better for smaller sample sizes and less varying time sequences. The application of the model to bladder cancer recurrence data revealed a significant effect of prior tumor recurrence on the probability of subsequent recurrences. For more information, readers can refer to the original article published in BMC Medical Research Methodology. [Extracted from the article]

A patent has been issued for an endcap for a liquid medicine-injecting tube. The endcap is designed to reduce the loss of liquid medicine during the priming process and allows medical staff to easily check if the priming has been completed. The endcap includes a flow passage, a filter member to remove air from the liquid medicine, a liquid-absorbing member, and an indicator that changes color when the air is discharged. The invention aims to improve the efficiency and safety of injecting liquid medicine into patients. The patent was filed by inventor Yong Hyun Kim and assigned to E-Wha Meditech Inc. [Extracted from the article]

A recent study conducted in Valencia, Spain, highlights the potential of an unsupervised Convolutional Auto Encoder (CAE) approach in improving the accuracy and efficiency of cancer diagnosis. The study focuses on Content-Based Medical Image Retrieval (CBMIR), which allows pathologists to search for similar histopathological Whole Slide Images (WSIs) to enhance diagnostic reliability. The customized CAE, known as Unsupervised CBMIR (UCBMIR), was evaluated using various techniques and achieved high recall and precision rates. The tool also demonstrated the ability to identify diverse patterns and retrieve images with the same cancer type. This research offers a promising step towards more transparent and accurate cancer diagnosis. [Extracted from the article]

A research perspective published in Oncotarget's Volume 14 discusses the relationship between melatonin and carcinogenesis in mice. The study highlights the inhibitory effect of melatonin on cancer in vivo, specifically on transplantable mammary tumors in mice. It also demonstrates that melatonin administration at night inhibits chemically induced mammary carcinogenesis in mice and rats. The researchers emphasize the importance of timing in melatonin administration for its applications in oncology. The study provides valuable insights into the effects of melatonin on cancer in mice and highlights the need for further research in this area. [Extracted from the article]

Smylio Inc. has filed a patent application for a saliva collection and testing system that aims to monitor patient wellness by collecting saliva samples over time. These samples can provide biomarkers for diseases like cancer and cardiovascular disease. The system includes a saliva analysis engine and a health monitoring engine to update the patient's health profile. Additionally, the article explores the potential benefits of using virtual reality (VR) technology in healthcare, such as pain management, rehabilitation, and mental health treatment. It also acknowledges the challenges and limitations of implementing VR in healthcare, including cost and accessibility, while emphasizing the need for further research and development in this area. [Extracted from the article]

A patent has been issued to Videra Surgical Inc. for a fiducial marker that can be used in oncological and other procedures. The marker is designed to help radiation oncologists accurately visualize the extent of the tumor bed after surgery, allowing for more precise targeting of radiation therapy. The marker consists of a flexible radiopaque filament that can be placed at the target tissue and observed under radiographic imaging. It can be used in various surgical procedures and is particularly useful in cases where a seroma, a fluid-filled pocket that can form after surgery, may not accurately represent the true tumor bed size and location. The marker can also be coated to enhance observation and prevent migration. [Extracted from the article]

These include the impact of age on cancer risk, the role played by inherited tumor predisposition syndromes, and the interaction of genetics and environmental exposures on cancer risk." Keywords: Menlo Park; State:California; United States; North and Central America; Business; Cancer; Cancer Risk; Carcinogenesis; Engineering and Scientific Consulting Companies; Environment; Epidemiology; Exponent Inc.; Genetics; Health and Medicine; Malignant Mesothelioma; Mesotheliomas; Oncology; Risk and Prevention EN Menlo Park State:California United States North and Central America Business Cancer Cancer Risk Carcinogenesis Engineering and Scientific Consulting Companies Environment Epidemiology Exponent Inc. Genetics Health and Medicine Malignant Mesothelioma Mesotheliomas Oncology Risk and Prevention 289 289 1 08/07/23 20230808 NES 230808 2023 AUG 8 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Oncology - Malignant Mesothelioma. [Extracted from the article]